Introduction
============

Gastric cancer (GC) is the fourth most commonly diagnosed malignancy and the second leading cause of cancer-related mortality worldwide [@B1], [@B2]. Existing therapeutic methods, such as surgery or chemotherapy, are not satisfactory because of the advanced stage of the disease, and the fact that it is often accompanied by malignant proliferation, extensive invasion, and lymphatic metastasis when diagnosed [@B3], [@B4]. Therefore, it is essential to discover novel potential molecular markers that are more effective for treating patients with GC.

Keratins (Krts), including 28 type I and 26 type II keratins, are the intermediate filament forming proteins of epithelial cells, and constitute an indispensable part of cytoskeleton [@B5], [@B6]. Loss or mutations in keratins that cause or predispose to human diseases can lead to increased sensitivity to apoptosis and regulation of innate immunity [@B7]. In previous decades, the role of the keratin family in human cancers has been widely studied, and has caused great concern. For example, Krt14 was found to serve a pivotal role in the regeneration and tumourigenesis of bladder cancer [@B8]. A recent study reported that increased Krt7 expression might mediate lncRNA Krt7-AS induced GC progression [@B9]. Krt17 was originally discovered as a major constituent of basal cell skin carcinoma [@B10], and is a member of the type I acidic epithelial keratin family [@B11]. In normal human epithelia, Krt17 expression is identified in various glands, including the respiratory epithelium and urothelium, and Krt17 is regarded as a basal/myoepithelial cell keratin [@B12], [@B13]. In addition to its scaffolding function, the expression of Krt17 is closely related to several types of cancer, and it acts as an oncoprotein by controlling the ability of p27 (KIP1) to influence cervical cancer pathogenesis [@B14]. Existing literatures report Krt17 is involved in the tumourigenesis of skin tumors [@B15], breast cancer [@B16], esophageal squamous cell carcinoma [@B17], colorectal carcinoma [@B18], pancreatic ductal adenocarcinoma [@B19], amongst others. However, the role of Krt17 in the development of GC is yet to be elucidated.

In our study, we analysed the expression of Krt17 in GC tissues and the corresponding normal tissues. The clinicopathological significance was determined by examining the expression of Krt17 using immunohistochemical staining in large samples of gastric tissue. In addition, we further elucidated the biological impact of Krt17 on GC cell lines.

Material and methods
====================

In silico analysis using the The Cancer Genome Atlas (TCGA) and ONCOMINE databases
----------------------------------------------------------------------------------

To investigate the expression pattern of Krt17 in GC, we used two datasets (<https://tcga-data.nci.nih.gov/>) ([www.oncomine.com/](http://www.oncomine.com/)). Data was collected and analysed using R 3.0.2 software. Krt17 gene expression in GC tissues and normal tissues were compared according to the standard calculation method as previously described. [@B20].

Clinical tissue samples
-----------------------

Tissue microarrays consisting of 569 GC samples were all obtained from the Renji Hospital (Shanghai, China) between January 2005 and December 2011. An additional 20 freshly-frozen GC tissues and matched non-cancerous tissues were also obtained from patients who underwent surgical resection at the Renji Hospital. None of these patients had received radiotherapy, chemotherapy, hormone therapy or other related anti-tumour therapies before surgery. None of these patients had additional cancers diagnoses. Postoperative adjuvant therapies were performed, according to standard schedules and doses. Patients were followed-up every 6 months by telephone or at outpatient clinic till July, 2015 or dead. Patients\' death information was obtained from their family. The follow-up time was calculated from the date of surgery to the date of death, or the last known follow-up. All samples were collected with participants\' written informed consent, and the experiments were approved by the local ethics committee of the Renji Hospital, Shanghai Jiaotong University School of Medicine.

Tissue microarrays construction
-------------------------------

Tissue microarrays were constructed by Shanghai Zhuoli Biological Technology Co. Ltd. (Shanghai, China). Tissue paraffn blocks of Krt17 samples from 569 cases were stained with hematoxylin-eosin to confrm the diagnoses and marked at fixed points with most typical histological characteristics under a microscope. Two 1.5-mm cores per donor block were transferred into a recipient block tissue microarray, and each dot array contained fewer than 160 dots. Three-micron-thick sections were cut from the recipient block and transferred to glass slides with an adhesive tape transfer system for ultraviolet cross-linkage.

Inmunohistochemistry (IHC) staining
-----------------------------------

IHC staining was performed according to a previously described procedure [@B21]. Krt17 rabbit polyclonal antibody (1:200, Proteintech, USA), PCNA (1:1000, Abcam, USA), cleaved caspase-3 (1:1000, CST, USA) were used. All sections were observed and imaged using a microscope (Axio Imager: Carl Zeiss). Scoring was conducted according to the ratio of positively stained cells (0 = negative, 1 = 1-25% of cells, 2 = 26-50% of cells, 3 = 51-75% of cells and 4 = 76-100% of cells were stained) and staining intensity (no staining scored 0, weakly staining scored 1, moderately staining scored 2 and strongly staining scored 3). The final score of Krt17 was designated using the proportion of positive cell score × staining intensity score as follows: "-" for a score of 0-2, "+" for a score of 3-5, "+ +" for a score of 6-9 and "+ + +" for a score of \> 9. Low expression was defined as a total score \< 6 and high expression as a total score ≥ 6. These scores were determined in a blinded manner by two senior pathologists and mean percentage values of two scores were taken.

Cell culture
------------

GC cell lines SGC-7901, MKN45, MGC-803, BGC823, and HGC-27 were gifted from the Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine. The immortalized human gastric mucosal cell line GES-1 and AGS were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cells were routinely cultured with RPMI-1640 medium supplemented with 10% fetal bovine serum and 1% antibiotics (100 μg/mL streptomycin and 100 units/mL penicillin) at 37˚C in an incubator with a 5% CO2 atmosphere.

Establishment of stable Krt17-slienced cell lines
-------------------------------------------------

Short hairpin RNA (ShRNA) sequences targeting Krt17 (Krt17-sh1:5′-GCCAGUACUACAGGACAAUTT-3′; Krt-sh2:5′-GGUGCGUACCAUUGUGGAATT-3′; and a negative control sequence (control: 5′-TTCTCCGAACGTGTCACGT-3′) were synthesized and transfected into pGLVU6/Puro vector (GenePharma corporation, Shanghai, China). 293T cells were utilized for virus packaging after co-transfection of target plasmids using Lipofectamine 3000 (Invitrogen). Viruses were obtained at 48 h after transfection. The target cells (1 × 10^5^), including SGC7901 and AGS cells, were infected with the filtered lentivirus. The stable Krt17 silenced cells were selected by culturing with 2 μg/mL puromycin (Sigma-Aldrich) for 2 weeks and the silencing effects were determined by qRT-PCR and western blot analysis.

qRT-PCR
-------

We extracted total cellular mRNA using TRIzol reagent (Takara) and then performed reverse transcription with the PrimeScript RT-PCR kit (Takara) according to the protocol provided. The mRNA expression of Krt17 (sense: 5′-GGTGGGTGGTGAGATCAATGT-3′; anti-sense: 5′- CGCGGTTCAGTTCCTCTGTC-3′) was determined by real-time PCR using SYBR Premix Ex Taq (Takara) and a 7500 real-time PCR system (Applied Biosystems) at the following cycling settings: one initial cycle at 95˚C for 10 s, 40 cycles at 95˚C for 5 s, followed by 30 s at 60˚C. Data given were normalized to 18s expression (sense: 5′-TGCGAGTACTCAACACCAACA-3′; anti-sense: 5′-GCATATCTTCGGCCCACA-3′) and represent the average of 3 repeated experiments, and were calculated with the 2-ΔΔCT method.

Western blotting
----------------

Total protein of cells and tissue were extracted using a total protein extraction buffer (Beyotime, China). Cell lysates were separated by 10% SDS-PAGE gel electrophoresis and transferred to a nitrocellulose membrane. The membranes were blocked with 5% nonfat milk and incubated with the primary antibodies and then incubated with species-specific secondary antibodies. Image J software was used to quantify the results. Antibodies and their corresponding concentrations used were as follows: Krt17 (1:1000, Proteintech, USA), Bcl2 (1:1000, CST, USA), Bax (1:1000, CST, USA), Bcl-xl (1:1000, CST, USA), Cleaved caspase-3 (1:1000, CST, USA), Cyclin D1 (1:1000, Sigma, USA), Cyclin E (1:1000, Sigma, USA), IRDye680 anti-mouse (1:20000, LI-COR) and IRDye800 anti-rabbit (1:10000, LI-COR). β-actin (1:1000, CST, USA) was used as a control to ensure the equal loading of protein.

Cell viability assay (CCK8 assay)
---------------------------------

NC and shKrt17 GC cells were seeded into 96-well plates at a density of 2000-3000 cells per well with 100μL medium containing 10% serum. Each group contained 5 wells. Cell Counting Kit-8 (CCK-8, Dojindo, Japan) solution (10μL) was added to each well after 0, 24, 48, 72 and 96h, respectively. Cell viability was measured using a microplate reader (BIO-TEK) at the absorbance of 450 nm. This experiment was repeated twice at each time point.

*In vivo* tumour xenograft model
--------------------------------

Six-week-old male nude (nu/nu) mice (SLAC, Shanghai, China) were injected subcutaneously in the right flank with the stable cell clones of SGC7901 cells at a density of 5×10^6^, infected with SGC7901-NC or SGC7901-sh1 in 100µL sterilized phosphate-buffered saline for each nude mouse. Each group contained 6 mice, and the tumor weights were measured and recorded. Six weeks later, all mice were sacrificed and their tumors were dissected, fixed with phosphate-buffered neutral formalin, embedded in paraffin and prepared for standard histological examination. Mice were experimented upon and housed according to protocols approved by the East China Normal University Animal Care Commission.

*In vitro* Migration and Invasion Assays
----------------------------------------

For the transwell migration assay, 20000 NC and sh-Krt17 GC cells were seeded on the top chamber of each insert with the noncoated membrane (Millicell). Cells were trypsinized and resuspended in medium and 600-800μL medium supplemented with 10% fetal bovine serum. 24h later any cells remaining in the top chambers or on the upper membrane of the inserts were carefully removed. After fixation and staining in a dye solution containing 0.1% crystal violet and 20% methanol, cells adhering to the lower membrane of the inserts were counted and imaged using an IX71 inverted microscope (Olympus Corp. Tokyo, Japan). We carried out invasion assays by adding 100μL matrigel (BD Bioscience, Franklin Lakes, NJ) into top chamber of transwell and placed 40000 NC and shKrt17 GC cells onto the matrigel. 24 h later, the transwell invasion assay was terminated and we proceeded with staining.

Wound healing assay
-------------------

Cells were seeded into 6-well plates and incubated at 37˚C in 5% CO2 for 24 h until they were 80-90% confluent. Wounds were created on these cells with a sterile pipette tip and cells were cultured in the medium without FBS. After wounding (time 0 h) and 24 h, photographs were taken to assess the ability of the cells to migrate into the wound area (original magnification, 100 ×). Experiments were performed in triplicate and repeated at least three times.

Cell cycle and apoptosis analysis
---------------------------------

For cell cycle analysis, transfected cells were cultured for 24 h and then collected and fixed in 70% ethanol at 20˚C for 24 h. The fixed cells were washed with phosphate-buffered saline twice before staining with 50μg/mL propidium iodide (Kaiji, NanJing, China). Cell-cycle distribution was analysed by flow cytometry (FACSCalibur, Becton Dickinson, MD, USA). For the apoptosis assay, cells were stained with propidium iodide and Annexin V-fluorescein isothiocyanate (BD Pharmingen) in accordance with the manufacturer\'s instructions. In brief, the cells were collected and stained with 5µL Annexin V-FITC and 5µL PI for 20 min in the dark and then immediately analysed by flow cytometry.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS version 21.0 (IBM Corporation) and GraphPad Prism5 (San Diego, CA) software. Clinicopathological characteristics were analysed by the chi-square test. Survival curves were evaluated using the Kaplan-Meier method, and analysed by the log-rank test. Cox\'s proportional hazards modeling of factors potentially related to survival were conducted to calculate hazard ratios (HR). Differences were compared using a two-tailed Student\'s*t* test. All *P*-values were determined from 2-tailed tests and differences with a*P*-value \< 0.05 was considered to be statistically significant.

Results
=======

The expression of Krt17 is upregulated in GC tissues
----------------------------------------------------

To evaluate the expression status of Krt17 in human GC tissues, we first analysed the mRNA expression levels of Krt17 in two independent microarray datasets, including the TCGA and ONCOMINE databases. The results revealed that the expression levels of Krt17 were significantly elevated in tumor tissues compared with normal tissues in both independent datasets. (*P* \<0.001, *P* \<0.001), (Fig. [1](#F1){ref-type="fig"}A-E). We further examined the protein expression levels of Krt17 in 20 pairs of GC and adjacent normal tissues. Consistent with the data from the TCGA and ONCOMINE databases, the protein expression levels of Krt17 in GC tissues was also increased in 70% (14/20) compared to the adjacent normal tissue (Fig. [1](#F1){ref-type="fig"}F). We then performed an immunohistochemical analysis of a tissue microarray that contained 569 GC samples and found Krt17 was highly expressed in the 321 (56.41%) of GC samples, and the rest 248 (43.59%) samples showed a low expression level (Fig. [2](#F2){ref-type="fig"}). The aforementioned results demonstrated that both the mRNA and protein levels of Krt17 were significantly upregulated in GC tissues.

The expression of Krt17 is correlated with clinicopathological features and acts as a poor prognostic factor in patients with GC
--------------------------------------------------------------------------------------------------------------------------------

In order to obtain a deeper understanding of the clinical significance of Krt17, the chi-square test was used to analyse the association between Krt17 expression and the clinicopathological parameters of patients with GC. We found that Krt17 expression in GC tissues closely correlated with the tumor size (*P* \< 0.01), depth of invasion (T) (*P* \< 0.001), lymph node metastasis(N) (*P* \< 0.001), TNM stage (*P* \< 0.001) and vascular invasion (*P* \< 0.05). However, no significant difference was detected between Krt17 expression and age or gender (Table [1](#T1){ref-type="table"}).

To determine the prognostic value of Krt17 for GC, the relationship between Krt17 expression and the clinical follow-up data was analysed using Kaplan-Meier analysis and the log-rank test. The results demonstrated that high expression of Krt17 was inversely associated with overall survival (OS) (n = 569, *P* \< 0.001, Fig. [3](#F3){ref-type="fig"}A), which indicated that patients with higher Krt17 levels had significantly poorer OS than those with lower Krt17 levels. We also determined that high expression of Krt17 was remarkably associated with poor OS, regardless of TNM stage, lymph node metastasis, neural invasion, and vascular invasion (Fig. [3](#F3){ref-type="fig"}B-I).

To directly identify the risk factors associated with OS in patients with GC, univariate and multivariate analyses were performed to confirm whether Krt17 was an independent risk factor for poor prognosis. Univariate Cox regression analyses showed that lauren type, tumor size, depth of tumor, lymph node metastasis, vascular invasion, neural invasion, expression of Krt17 were significantly associated with OS (Table [2](#T2){ref-type="table"}). Furthermore, a multivariate Cox regression analysis identified that tumor size, depth of tumor, lymph node metastasis, vascular invasion, neural invasion, expression of Krt17 were independent predictors of OS in patients with GC (Table [2](#T2){ref-type="table"}).Taken together, these data indicated that upregulated expression levels of Krt17 predicted poor prognosis and might contribute to tumor progression in GC.

Silencing of Krt17 suppresses GC cell proliferation *in vitro* and tumor growth*in vivo*
----------------------------------------------------------------------------------------

To achieve a better understanding of the biological function of Krt17, we detected Krt17 expression in six GC cell lines using RT-PCR and western blotting. Consistent with the findings in GC tissues, Krt17 expression was upregulated in all six GC cell lines compared with the nonmalignant GES-1 cells (Fig. [4](#F4){ref-type="fig"}A). Two GC cell lines with relatively higher Krt17 expression (SGC7901 and AGS cells) were selected for loss-of-function analysis. SGC7901 and AGS were transfected with shKrt17 (1, 2), designated as sh1, sh2, and a mock vector, which was marked as NC. The silencing effects of the shRNAs in two cell lines were detected by RT-PCR and western blotting, which showed that Krt17 mRNA and protein expression levels were both significantly decreased by sh1 and sh2 (Fig. [4](#F4){ref-type="fig"}B).

To explore the effect of Krt17 on GC cell growth, SGC7901 and AGS cell lines were transfected with sh1 and sh2, and were used to detect cell proliferation using CCK8 assay. The results showed that reducing expression of Krt17 significantly suppressed the proliferation of the SGC7901 and AGS cells *in vitro* (*P*\<0.001) (Fig. [4](#F4){ref-type="fig"}C-D), and we further confirmed the inhibitory role of silencing Krt17 in GC cells proliferation *in vivo* by subcutaneously inoculating SGC7901-sh2 and NC cells into nude mice. After 30 days, tumors derived from sh2 cells were remarkably smaller than those derived from control cells (Fig. [4](#F4){ref-type="fig"}E). The average tumor weights and volumes in SGC7901/NC mice were 0.48 g ± 0.06 g and 0.30± 0.05 cm^3^, in contrast to 0.05 ± 0.03 g and 0.05 ± 0.02 cm^3^ in SGC7901/sh1 mice (*P* \< 0.01) (Fig. [4](#F4){ref-type="fig"}F). Krt17 expression in the tumors was determined using IHC staining, and the results showed that Krt17 expression levels in SGC7901/sh1 derived tumors was markedly lower than NC derived tumors. Moreover, tumor regression was accompanied with significantly increased expression levels of cleaved caspase3, a key executioner of apoptosis, and reduced expression of the proliferation index, PCNA (Fig. [4](#F4){ref-type="fig"}G).

Taken together, our data demonstrated that silencing Krt17 in GC cells suppressed cell proliferation *in vitro* and reduced tumourigenicity *in vivo*.

Silencing of Krt17 reduces the migration and invasive capacity of GC cells *in vitro*
-------------------------------------------------------------------------------------

In order to determine whether Krt17 influenced the migration and invasive ability of GC cells, we performed transwell assays and wound healing assays. The results showed knockdown of Krt17 notably blocked the migration and invasion of SGC7901 and AGS cells compared with the NC (Fig. [5](#F5){ref-type="fig"}A-I), which indicated that Krt17 promoted a more migratory and invasive phenotype in GC cells.

Silencing of Krt17 induces apoptosis and cell-cycle arrest at G1/S phase of GC cells
------------------------------------------------------------------------------------

We examined the contribution of apoptosis to the observed growth inhibition of Krt17 silenced cells by using flow cytometry with Annexin V and PI double staining. Krt17-silenced SGC7901 cells (Krt17-Sh1, Krt17-Sh2) acquired a much higher apoptosis ratio compared with SGC7901 cells transfected with NC (Fig. [6](#F6){ref-type="fig"}A). This phenomenon was also observed in Krt17-silenced AGS cells, where the proportions of both early apoptotic cells and late apoptotic cells had been significantly increased compared with the control NC-transfected AGS cells (Fig. [6](#F6){ref-type="fig"}B).The noticeable inhibition of cell proliferation by the knockdown of Krt17 also prompted us to assess the effects of Krt17 on cell-cycle distribution of GC cells, downregulation of Krt17 levels in SGC7901 cells increased the percentage of cells in G1/G0 phase compared with controls and decreased the percentage of cells in S phase (Fig. [6](#F6){ref-type="fig"}C). The reduction of Krt17 levels in AGS cells decreased the percentage of cells in S phase and increased the percentage of cells in G1/G0 phase (Fig. [6](#F6){ref-type="fig"}D). We further examined the expression of apoptosis regulators and several cell-cycle regulators by western blotting, and the results showed that the reduction of Krt17 in both SGC7901 and AGS cells decreased the levels of cyclin E, cyclin D1, and anti-apoptotic protein Bcl2, while causing increased expression of apoptotic proteins Bax and cleaved caspase-3 (Fig. [6](#F6){ref-type="fig"}E).

Discussion
==========

Krt17 is a member of type 1 acidic epithelial keratin family, which acts as a promoter of epithelial proliferation, and has been identified as an oncogene, participating in several processes involved in the occurrence of tumors. To date, Krt17 has been reported to be overexpressed in malignant lesions of the cervix, and plays a role in cervical tumourigenesis [@B22]. Similarly, Krt17 has been found in a poor prognostic phenotype of human colorectal carcinoma [@B18]. Previous studies reported that Krt17 was frequently expressed in the cytoplasm of tumor cells in patients with GC, and may correlate with tumor progression [@B23]. However, its exact biological role in GC remains elusive.

The abilities to predict outcome and to identify key players in biological mechanisms that lead to poor outcome are two important objectives in cancer research [@B24]. In our study, we first analysed GC microarray data from several different databases and found that mRNA expression of Krt17 was significantly upregulated in GC tissues compared to normal tissues. Furthermore, we ascertained that expression of Krt17 in a large panel of GC samples (569 cases) was positively correlated with the TMN stage, lymphatic metastasis, depth of invasion and vascular invasion. Noticeably, Kaplan-Meier survival analysis indicated that patients with high Krt17 expressions level exhibited a remarkable shorter survival duration than those displaying low Krt17 expression levels, indicating that Krt17 may participate in the development of GC.

Krt17 has been regarded to be of great importance in terms of protein synthesis and cell growth, and thus may have an important influence on cell viability and function. An important study demonstrated that Krt17 positively regulated the cell size and growth of keratinocytes by binding to the adapter protein SFN by stimulating the Akt/mTOR pathway [@B25]. Recently, Krt17 was established to strengthen the migration and invasive capacity of oral cancer cells via inducing epithelial-mesenchymal transition [@B26]. With regard to the current study, to further elucidate the potential effects of Krt17 in GC cell lines, we established stable Krt17 silencing of an SGC-7901 cell clone and AGS cell clone to perform loss of function experiments. Our results showed that the proliferative capacity of GC cells was significantly decreased in both *in vitro* and *vivo*, and the migration and invasive capacity declined remarkably after Krt17 was silenced *in vitro*. IHC analysis of subcutanuous tumors indicated that PCNA (proliferation index) expression was reducing after Krt17 was silenced, while cleaved caspase3, an important apoptosis index, was increased. In conclusion, our data demonstrated that Krt17 could promote the proliferation, migration, and invasion of GC cells.

Apoptosis, or programmed cell death, is thought to be involved in various biological processes during tumor pathogenesis [@B27]. The imbalance of cell apoptosis and proliferation is a crucial event in the progression of cancer. In our experiments, we discovered that silencing Krt17 greatly triggered apoptosis in both SGC7901 and AGS cell lines, which indicated that Krt17 inhibited apoptosis in human GC. Moreover, we found that silencing of Krt17 induced apoptosis was associated with altering the expression of the Bcl2 family. The Bcl2 family of proteins is a group of upstream regulators of MOMP that includes both pro-and anti-apoptotic components that predominantly mediate the mitochondrial (intrinsic) apoptotic pathway [@B28], [@B29]. Apoptotic protein Bax, as well as cleaved caspase-3, were upregulated, and downregulation of the anti-apoptotic proteins Bcl2 and Bcl-xl were determined by western blot analysis.

We then observed that silencing of Krt17 could notably induce cell cycle arrest at G0/G1 phase. Pathological regulation of cell-cycle processes is an essential aspect of cancer cells [@B30]. The G1/S transition is vital for cell proliferation and its disorder could lead to the carcinogenesis of various human cancers [@B31]. Our evaluation of potential mechanisms underlying the influences of Krt17 silencing on the suppression of human GC cell proliferation were focused on the expression of cell cycle-related regulators, and we found that cyclin E and cyclin D1, which were reported to promote cell cycle progression through inducing the G1-S phase transition [@B32], were significantly downregulated with the silencing of Krt17.

In conclusion, our study demonstrated that Krt17 was significantly upregulated in GC tissues, and that Krt17 expression could serve as an independent prognostic factor in patients with GC. Furthermore, our findings suggest that silencing of Krt17 had a suppressive effect on tumourigenesis in GC cell lines and inhibited cell growth both *in vitro* and *in vivo*. Moreover, Krt17 could regulate cell cycle and modulate cell cycle proteins.

Therefore, the current study revealed that Krt17 may act as an oncogene in GC, further studies to clarify the molecular mechanism may facilitate the development of a new candidate for targeted therapy for GC.
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![The expression of Krt17 is significantly upregulated in GC tissues. A: The mRNA expression of Krt17 is upregulated in tumor tissues compared with the normal tissues revealed using the TCGA dataset. B: The mRNA expression of Krt17 is upregulated in 32 matched tumor and non-tumor tissue revealed using the TCGA dataset. C: Krt17 is upregulated in GC intestinal type compared with normal gastric tissues. D: Krt17 is increased in GC diffuse type compared with normal gastric tissues. E: Compared with normal gastric mucosa, Krt17 is upregulated in GC intestinal type. F: Krt17 protein expression is elevated in 20 paired GC tissues and normal tissues from Renji hospital via western blotting.](jcav09p0346g001){#F1}

![Krt17 expression in GC tissue samples. A-D: Representive images of Krt17 expression in GC are shown at 200x and 400x magnification,respectively. A: GC, scored as (-); B: GC, scored as (+); C: GC, scored as (++); D: GC, scored as (+++).](jcav09p0346g002){#F2}

![Kaplan-Meier analysis of overall survival in GC patients. A: Krt17 expression is correlated with overall survival in GC patients and high expression level of Krt17 was significantly correlated with poor survival of GC; B-I Correlation between Krt17 expression and overall survival is independent of clinical stage (B-C), lymphatic metastasis (D-E), neural invasion (F-G) and vascular invasion (H- I). P-values were calculated by log-rank test.](jcav09p0346g003){#F3}

![Silencing of Krt17 suppressed gastric cancer cell proliferation *in vitro* and tumor growth *in vivo*. A: qRT-PCR and western blotting showed the Krt17 expression in 7 GC cell lines. B: Krt17 knockdown efficiency was confirmed by qRT-PCR and western blot in SGC7901 and AGS cells. C: The cell proliferation of NC and sh1, sh2 groups in SGC7901 and AGS cells were evaluated by CCK8 assay at 0, 24, 48, 72, 96 h, respectively. D: Photographs of tumors from mice inoculated with SGC7901/NC and SGC7901/sh2 cells. E: Tumor volumes and tumor weights of NC and sh2 groups from D, n = 6. F: Representative images of Krt17, cleaved caspase3 and PCNA in tissues from NC and sh2 mice detected by IHC staining. Compared with NC mice, decreased expression of PCNA and increased expression of cleaved caspase3 were observed in the tissue samples of sh2 (\**P* \< 0.05, \*\**P* \< 0.01).](jcav09p0346g004){#F4}

![Silencing of Krt17 inhibited migration and invasion in GC cell. A-B: Representative wound healing images of SGC7901 and AGS at 0 and 24 h, respectively, the cell boundary was marked by the dotted black line. C: Relative migration distance was analyzed in SGC7901 cells and AGS cells respectively. D-F: Representative migration images of Krt17 silenced and NC cells. G-I Representative invasion images of Krt17 silenced and NC cells. Original magnification: 200 ×. Calculation of cell number were performed with three randomly selected fields. Data are means ± SD (\*P \< 0.05, \*\*P \< 0.01).](jcav09p0346g005){#F5}

![Effect of Krt17 on the cell cycle and apoptosis in GC cells. A-B: Downregulation of Krt17 significantly increased apoptosis in SGC-7901 and AGS cells, the statistical results are shown on the left (\*P \< 0.05, \*\*P \< 0.01). C-D: Sliencing of the Krt17 in SGC-7901 and AGS cells decreased cells at G0/G1 phase and increased cells at S phase, the statistical results are shown on the left (\*P \< 0.05, \*\*P \< 0.01). E: Western blot analysis of cell-cycle regulators cyclin E, cyclin D1, the expression of Bcl2, Bax, Bcl-xl and cleaved caspase3 were also determined.](jcav09p0346g006){#F6}

###### 

Correlations between Krt17 expression and clinical parameters in 569 GC patients.

  Clinicopathological variables      Krt17 Expression   *P*          
  ---------------------------------- ------------------ ------------ -------------
  **Age**                                                            
  ≥65                                94(41.59)          132(58.41)   0.49
  \<65                               154(44.90)         189(55.10)   
  **Lauren type**                                                    
  Intestinal type                    91(50.28)          90(49.72)    0.701
  Diffuse type                       157(40.46)         231(59.54)   
  **Gender**                                                         
  Male                               168(43.08)         222(56.92)   0.717
  Female                             80(44.69)          99(55.31)    
  **Tumor size (cm)**                                                
  \<5                                150(49.67)         152(50.33)   **0.002**
  ≥5                                 98(36.70)          169(63.30)   
  **Histological differentiation**                                   
  Well                               79(49.38)          81(50.62)    0.091
  Moderate/Poor                      169(41.32)         240(58.68)   
  **Depth of invasion (T)**                                          
  T1                                 52(68.42)          24(31.58)    **\<0.001**
  T2                                 35(43.75)          45(56.25)    
  T3                                 60(39.74)          91(60.26)    
  T4                                 101(38.55)         161(61.45)   
  **Lymph node metastasis(N)**                                       
  N0                                 121(56.02)         95(43.98)    **\<0.001**
  N1                                 45(42.86)          60(57.14)    
  N2                                 38(33.33)          76(66.67)    
  N3                                 44(32.84)          90(67.16)    
  **TNM stage**                                                      
  I                                  72(60.50)          47(39.50)    **\<0.001**
  II                                 80(48.48)          85(51.52)    
  III                                94(33.69)          185(66.31)   
  IV                                 2(33.33)           4(66.67)     
  **Distant metastasis**                                             
  Absent                             246(43.69)         317(56.31)   0.701
  Present                            2(33.33)           4(66.67)     
  **Vascular invasion**                                              
  Negative                           217(45.68)         258(54.32)   **0.023**
  Positive                           31(32.98)          63(67.02)    
  **Neural invasion**                                                
  Negative                           225(45.00)         275(55.00)   0.071
  Positive                           23(33.33)          46(66.67)    

\**P*\<0.05 (bold values) are statistically significant

###### 

Univariate and multivariate analysis of prognostic parameters for OS in 569 GC patients by Cox proportional hazards regression.

                                           Univariate analysis                 Multivariate analysis                            
  ---------------------------------------- --------------------- ------------- ----------------------- -- ------- ------------- ---------
  Age (\<65,\>=65)                         0.856                 0.721-1.016   0.075                      \-      \-            \-
  Gender (male,female)                     0.988                 0.827-1.180   0.892                      \-      \-            \-
  Lauren type (Intestinal, Diffuse)        1.215                 1.018-1.451   0.031                      0.992   0.823-1.196   0.933
  Tumor size (\<5,≥5cm)                    1.598                 1.354-1.887   \<0.001                    1.299   1.071-1.582   0.008
  Depth of invasion (T1,T2,T3,T4)          1.105                 1.027-1.188   0.008                      0.911   0.832-0.998   0.046
  Lymph node metastasis (N1,N2,N3,N4)      1.386                 1.292-1.487   \<0.001                    1.299   1.194-1.413   \<0.001
  Vascular invasion (negative, positive)   2.208                 1.763-2.765   \<0.001                    1.539   1.203-1.970   0.001
  Neural invasion (negative, positive)     1.89                  1.462-2.443   \<0.001                    1.579   1.206-2.067   0.001
  Distant metastasis (absent,present)      1.632                 0.729-3.654   0.234                      \-      \-            \-
  Expression of krt17 (low, high)          1.454                 1.231-1.717   \<0.001                    1.336   1.128-1.582   0.001

[^1]: Competing Interests: The authors have declared that no competing interest exists.
